文献速递消化系统肿瘤

健康相关生活质量评估应如何在晚期结直肠癌临床试验中使用

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.
PubMed 文献 · Ann Oncol · 2017-01-01

本文讨论健康相关生活质量(HRQoL)在晚期或转移性结直肠癌III期临床试验中的应用,阐述HRQoL评估方法、分析及结果呈现的重要性,并探讨将HRQoL作为主要或共同主要终点以支持无进展生存结果和评估晚期疾病治疗疗效的相关性。

要点

  • HRQoL包含患者报告的疾病或其治疗对躯体、情感和社会健康的影响。
  • HRQoL可为传统肿瘤反应和生存终点提供补充临床数据及预测和预后价值。
  • 本文探讨将HRQoL作为主要/共同主要终点以支持无进展生存结果。

核心结论

  • HRQoL可作为晚期结直肠癌临床试验中补充肿瘤反应和生存终点的以患者为导向的终点。
  • 将HRQoL作为主要/共同主要终点可支持无进展生存结果并评估晚期疾病治疗疗效。

研究设计与样本

  • 本文为综述,检索范围未报告,聚焦HRQoL在III期转移性结直肠癌临床试验中的使用。

主要发现

  • 过去几年多种实体瘤的III期试验评估了HRQoL在传统肿瘤反应和生存终点之外的增量价值。
  • HRQoL可提供补充临床数据及更精确的预测和预后价值。

关键数值与推荐

  • HRQoL包含患者报告的疾病或其治疗对躯体、情感和社会健康的影响。
  • HRQoL作为终点对临床医生和患者实现精准医学理念有用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Traditionally, the efficacy of cancer treatment in patients with advance or metastatic disease in clinical studies has been studied using overall survival and more recently tumor-based end points such as progression-free survival, measurements of response to treatment. However, these seem not to be the relevant clinical end points in current situation if such end points were no validated as surrogate of overall survival to demonstrate the clinical efficacy. Appropriate, meaningful, primary patient-oriented and patient-reported end points that adequately measure the effects of new therapeutic interventions are then crucial for the advancement of clinical research in metastatic colorectal cancer to complement the results of tumor-based end points. Health-related quality of life (HRQoL) is effectively an evaluation of quality of life and its relationship with health over time. HRQoL includes the patient report at least of the way a disease or its treatment affects its physical, emotional and social well-being. Over the past few years, several phase III trials in a variety of solid cancers have assessed the incremental value of HRQoL in addition to the traditional end points of tumor response and survival results. HRQoL could provide not only complementary clinical data to the primary outcomes, but also more precise predictive and prognostic value. This end point is useful for both clinicians and patients in order to achieve the dogma of precision medicine. The present article examines the use of HRQoL in phase III metastatic colorectal cancer clinical trials, outlines the importance of HRQoL assessment methods, analysis, and results presentation. Moreover, it discusses the relevance of including HRQoL as a primary/co-primary end point to support the progression-free survival results and to assess efficacy of treatment in the advanced disease setting.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bonnetain F, Borg C, Adams RR, et al. How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. Ann Oncol. 2017. PMID: 28430862. doi:10.1093/annonc/mdx191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。